Master Class on Intellectual Property for New Ventures: How to make money from your IP portfolio?

About this event

IP is one of the key components in both early-stage and well-established companies, therefore for medtech, digital health and biotech start-ups its crucial to develop a strong patent strategy right from the start.

ELAVITY jointly with the law firm Vossius & Partner, Swiss Federal Institute of Intellectual Property and Novateur Ventures, invites you to this Masterclass on Intellectual Property for New Ventures. A variety of topics will be covered as described in below and the strategic importance of IP and licensing in the context of fundraising will be highlighted.

Topics:

• Deep dive into Intellectual Property definition as a key value driver
• Short introduction to the common IP rights else than patents (trademarks, designs and copyright)
• Patents and patentability criteria (technicality, industrial application, novelty and inventive steps)
• Applications of Intellectual Property
• How to use IP to protect your business
• Common strategies to extend protection beyond the 20-year term
• Developing a compelling IP Portfolio
• How to make money from your IP Portfolio

The June VANTEC event will feature thought leaders who will provide some insights into the trends and future of the life and health sciences sector; followed by presentations from life sciences and healthtech companies. Join us for an afternoon of investor panels, pitches, and networking.

Follow the news and you know: Scientists are more than just chipping away at cancer. They are kicking down the barricades. Cell therapies are, at long last, delivering lasting remissions in a few indications. Small molecules and antibodies with new mechanisms of action – sometimes in clever combination – are raising the bar, making cancer more of a chronic and tolerable disease. Underlying information on gene mutations, dysregulated protein networks and the tumor microenvironment provide a vivid glimpse of malignancy at the molecular level, and a wellspring for new therapeutic ideas. Much of this progress is occurring here on the West Coast. Hear from the leaders in Big Biotech, venture capital, and emerging startups at The Seattle Cancer Summit, March 5 and at The Boston Cancer Summit, March 7. All proceeds go to the Mt. Everest Climb to Fight Cancer campaign at Fred Hutchinson Cancer Research Center.

Follow the news and you know: Scientists are more than just chipping away at cancer. They are kicking down the barricades. Cell therapies are, at long last, delivering lasting remissions in a few indications. Small molecules and antibodies with new mechanisms of action – sometimes in clever combination – are raising the bar, making cancer more of a chronic and tolerable disease. Underlying information on gene mutations, dysregulated protein networks and the tumor microenvironment provide a vivid glimpse of malignancy at the molecular level, and a wellspring for new therapeutic ideas. Much of this progress is occurring here on the West Coast. Hear from the leaders in Big Biotech, venture capital, and emerging startups at The Seattle Cancer Summit, March 5 and at The Boston Cancer Summit, March 7. All proceeds go to the Mt. Everest Climb to Fight Cancer campaign at Fred Hutchinson Cancer Research Center.

Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year.

Join SynBioBeta 2019 on October 1-3 in San Francisco to see how synthetic biology is disrupting consumer products, food, agriculture, medicine, chemicals, materials, and more.

The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

The Prix Galien USA Awards Ceremony launched in 2007 and the Awards Ceremony and Dinner is held annually at the New York City Museum of Natural History following the Galien Forum. In recognition of the development and discovery of products that improve the human condition, a committee of highly accomplished scientific leaders, inclusive of four Nobel Laureates, recognized winners in three categories: “Best Pharmaceutical Product,” “Best Biotechnology Product,” and “Best Medical Technology.”

As Europe’s largest life science partnering conference, BIO-Europe offers countless opportunities to engage with global life science partners. Empower yourself with knowledge from key biotech and pharma leaders who will discuss the latest industry trends in workshops and panels.

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

What is today known as the annual J.P. Morgan Healthcare Conference began in 1983 and was hosted by Hambrecht & Quist (H&Q). H&Q was acquired by Chase in 2000 and a year later Chase was acquired by J.P. Morgan. At its infancy, the conference featured just 20 companies, had about 200 attendees and focused on the biotech industry.

Today, while it is still at the Westin St. Francis in San Francisco, the annual J.P. Morgan Healthcare Conference brings thousands of investors from around the world together. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.

This year’s theme is “Innovation Adoption – Accelerating Patient Outcomes”. Stakeholders include: Academia, Health Institutions, Government, Centres of Innovation, SMEs, Multi-national Corporations, Investors and Payers.

The highly successful fourteenth annual BIO-Europe Spring® international partnering conference was a fully digital event in the midst of the worldwide travel restrictions due to the global health emergency. In just 16 days, EBD Group transformed what would have been a Paris conference to a digital solution. 

For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive your business, and the insights you need to continue critical research and development. 

We may not be able to gather in person, but nothing stops innovation.

The LifeSciences BC Investor Summit, presented by Lumira Ventures brings together industry stakeholders from the healthcare innovation ecosystem for company pitching and fostering strategic partnerships with international investors. This signature event will profile more than 30 digital health, therapeutics, and medical technology entrepreneurs from British Columbia’s life sciences sector. 

Each of the selected companies will have the opportunity to present their company’s story and receive feedback and engagement from a wide range of investor stakeholders including, angel investors, venture capitalists, and corporate ventures from Japan, France, Hong Kong, China, the United States and Canada.

Please join Novateur Ventures Inc.'s Founder & Managing Director and Vice-Chair of LifeSciences BC, Ali Ardakani for the panel discussion on investment in the BC life sciences sector with some of the most active investors in the region.

 

Learning the “in’s and out’s” of fundraising is a key element of an entrepreneur's venture building journey. But even more important is building relationships with potential investors, as these are the champions that can provide guidance, open doors and provide valuable insights to navigate from what, when and how to fundraise.

Join our Reverse Pitch Roundtables following our Sneak-a-Peek presentations with Ali Ardakani of Novateur Ventures Inc. Ventures, Irene Dorsman of Angel Forum ™ Vancouver and Women's Equity Lab and Pieter Dorsman of Angel Forum ™ Vancouver and E-Fund. 

Join Novateur Ventures Inc.'s Managing Director Ali Ardakani and ESSA Pharma' s President & CEO David Parkinson on Wednesday, Feb 24, 1:30 PM - 2:00 PM (PST) for a session about the journey from discovery to successful clinical trials at the  LifeSciences BC Access to Innovation event.

Session 3: Part 2, Wednesday, Feb 24, 1:30 PM - 2:00 PM (PST)
Theme: "From Discovery to Successful Clinical Trials: ESSA Pharma’s Story"

Join Novateur Ventures Inc.'s Managing Director Ali Ardakani and Kardium Inc.' s CEO Kevin Chaplin on Wednesday, Feb 24, 12:30 PM - 1:00 PM (PST) for a session about successful medical device commercialization at the LifeSciences BC Access to Innovation event.